Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB
News Jul 04, 2012
The agreement gives Ferring rights to market the product globally with the exception of Japan and a small number of Asian markets. In consideration of the rights, Ferring will pay Albireo a significant upfront licensing fee, milestones and tiered double-digit royalties. Ferring will also be responsible for development costs in its territory.
The agreement is one of the biggest investments made by Ferring for licensing rights of a product. Ferring is a recognized leader in Inflammatory Bowel Disease (IBD) including ulcerative colitis and Crohn's disease, and aims to become a global player in the broader gastroenterology field. Ferring believes that the novel therapy elobixibat, which is targeting a currently under-served, but large patient population, will significantly strengthen its gastroenterology portfolio. Elobixibat is due to enter Phase III trials for the CIC indication and Phase IIB trials for the IBS-C indication shortly.
"Elobixibat perfectly complements our gastroenterology portfolio, which includes PENTASA(R) for IBD and PICOPREP(R) for bowel cleansing. We also have several promising products in our pipeline within gastroenterology," commented Michel Pettigrew, President of the Executive Board and COO at Ferring. "What is more, it fits well with our company philosophy of 'People Come First' -- in particular the patient, as it addresses a problem that affects from 15% up to almost a third of the population but that has seen little progress in treatment options over the years."
Dr. Jan Mattsson, Executive Director of the Board and COO of Albireo said "We are excited to enter into this agreement and look forward to collaborating with Ferring to bring this novel therapy to patients around the world suffering from CIC or IBS-C. Ferring has a long and strong track record in gastroenterology and we believe will be an ideal partner for Albireo and elobixibat in this territory."
Researchers Uncover Muscle Growth Inhibitor Activation Mechanism Aiding ALS Treatment EffortsNews
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for limiting muscle, is activated.READ MORE
Synthetic Horsepox Virus Could Lead to More Effective Smallpox VaccineNews
University of Alberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE